PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201700016CEBOLA therapeutics — Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals, Inc holds $-7,005,694 across 6 federal awards. Competition previously drew 2 offers. Set-aside status: NONE. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma
Awarding office
Department of Health and Human Services (HHS)
Agency
Regeneron Pharmaceuticals, Inc
Recipient
Sep 29, 2027
PoP end
$2.7M
Obligated
541711
NAICS
AN13
PSC
NONE
Set-aside
2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

NONE
Contract numberHHSO100201700016C
AgencyDepartment of Health and Human Services (HHS)
Awarding officeBarda - Aspr / Daappo / Barda Dcma
IncumbentRegeneron Pharmaceuticals, Inc
UEIN3F9MH7E6HD6
NAICS541711

No full NAICS 541711 intel page yet. Browse NAICS intelligence

PSCAN13
Place of performanceTARRYTOWN, NY
Related solicitation17100SOL00014
PoP end (current)Sep 29, 2027
Obligated$2.7M

EBOLA THERAPEUTICS is a federal NONE award for Department of Health and Human Services (HHS) held by Regeneron Pharmaceuticals, Inc. Estimated value $695.7M ($2.7M obligated). Current period of performance ends Sep 29, 2027. Last award drew 2 bidders. Place of performance: TARRYTOWN, NY. Related solicitation 17100SOL00014.

Recompete timing

Public
● Expiring in 367 days

Current PoP ends Sep 29, 2027 (367 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Bonuses end Sept 30

Want the durability read on HHSO100201700016C? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Regeneron Pharmaceuticals, Inc — $-7,005,694 obligated across 6 awards (firm-wide, all agencies).

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract HHSO100201700016C?

HHSO100201700016C (EBOLA therapeutics) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $695.7M, currently held by Regeneron Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HHSO100201700016C?

Barda - Aspr / Daappo / Barda Dcma awarded HHSO100201700016C to Regeneron Pharmaceuticals, Inc.

Who is the incumbent on HHSO100201700016C?

Regeneron Pharmaceuticals, Inc is the incumbent with $-7,005,694 across 6 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does Regeneron Pharmaceuticals, Inc’s HHSO100201700016C come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on HHSO100201700016C? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HHSO100201700016C